Levonorgestrel | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | |
Levonorgestrel | hsa00030 | Pentose phosphate pathway | 8.97E-03 | 1 | P11413 | G6PD | More | |
Levonorgestrel | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
Levonorgestrel | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
Levonorgestrel | hsa00071 | Fatty acid degradation | 3.77E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | |
Levonorgestrel | hsa00190 | Oxidative phosphorylation | 4.36E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
Levonorgestrel | hsa00220 | Arginine biosynthesis | 4.88E-02 | 1 | P49448 | GLUD2 | More | |
Levonorgestrel | hsa00250 | Alanine, aspartate and glutamate metabolism | 4.88E-02 | 1 | P49448 | GLUD2 | More | |
Levonorgestrel | hsa00471 | D-Glutamine and D-glutamate metabolism | 1.65E-02 | 1 | P49448 | GLUD2 | More | |
Levonorgestrel | hsa00480 | Glutathione metabolism | 1.35E-02 | 1 | P11413 | G6PD | More | |
Levonorgestrel | hsa00500 | Starch and sucrose metabolism | 1.00E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
Levonorgestrel | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | |
Levonorgestrel | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
Levonorgestrel | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
Levonorgestrel | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Levonorgestrel | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Levonorgestrel | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | |
Levonorgestrel | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.88E-05 | 2 | P40925, P15104 | MDH1, GLUL | More | |
Levonorgestrel | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Levonorgestrel | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
Levonorgestrel | hsa00910 | Nitrogen metabolism | 4.88E-02 | 1 | P49448 | GLUD2 | More | |
Levonorgestrel | hsa00920 | Sulfur metabolism | 3.18E-02 | 1 | Q16762 | TST | More | |
Levonorgestrel | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.35E-05 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | |
Levonorgestrel | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Levonorgestrel | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Levonorgestrel | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
Levonorgestrel | hsa01200 | Carbon metabolism | 2.91E-02 | 1 | P11413 | G6PD | More | |
Levonorgestrel | hsa01210 | 2-Oxocarboxylic acid metabolism | 3.43E-02 | 1 | P50213 | IDH3A | More | |
Levonorgestrel | hsa01230 | Biosynthesis of amino acids | 3.91E-02 | 3 | P51854, Q99707, P50213 | TKTL1, MTR, IDH3A | More | |
Levonorgestrel | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Levonorgestrel | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
Levonorgestrel | hsa03008 | Ribosome biogenesis in eukaryotes | 4.94E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
Levonorgestrel | hsa03040 | Spliceosome | 4.48E-08 | 14 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P29375 | JARID1A | Lysine-specific demethylase 5A | Q14562 | DHX8 | ATP-dependent RNA helicase DHX8 | 0.781 | P29375 | JARID1A | Lysine-specific demethylase 5A | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | 0.794 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | -0.76 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | O60508 | CDC40 | Pre-mRNA-processing factor 17 | 0.76 | P29375 | JARID1A | Lysine-specific demethylase 5A | O60508 | CDC40 | Pre-mRNA-processing factor 17 | 0.875 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.812 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | 0.787 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | -0.822 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P26368 | U2AF2 | Splicing factor U2AF 65 kDa subunit | -0.751 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.74 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | 0.712 | P29375 | JARID1A | Lysine-specific demethylase 5A | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | -0.749 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | 0.822 | P29375 | JARID1A | Lysine-specific demethylase 5A | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | 0.862 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.798 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84103 | SFRS3 | Serine/arginine-rich splicing factor 3 | -0.773 | P29375 | JARID1A | Lysine-specific demethylase 5A | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | 0.732 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | -0.822 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | -0.802 | P35610 | SOAT1 | Sterol O-acyltransferase 1 | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | 0.711 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | -0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43447 | PPIH | Peptidyl-prolyl cis-trans isomerase H | -0.766 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75643 | ASCC3L1 | U5 small nuclear ribonucleoprotein 200 kDa helicase | -0.745 |
|
Levonorgestrel | hsa03060 | Protein export | 3.28E-02 | 1 | Q15070 | OXA1L | More | |
Levonorgestrel | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | |
Levonorgestrel | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | |
Levonorgestrel | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa04014 | Ras signaling pathway | 9.55E-04 | 9 | P42338, P20827, P49767, P08069, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, IGF1R, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | |
Levonorgestrel | hsa04015 | Rap1 signaling pathway | 9.79E-05 | 14 | P20827, P49767, P08069, P06213, Q96FS4, P11215, P25116, Q8TEU7, Q13009, O00522, Q7LDG7, P42338, P08514, P19174 | EFNA1, VEGFC, IGF1R, INSR, SIPA1, ITGAM, F2R, RAPGEF6, TIAM1, KRIT1, RASGRP2, PIK3CB, ITGA2B, PLCG1 | More | |
Levonorgestrel | hsa04024 | cAMP signaling pathway | 4.25E-03 | 7 | P63092, P42338, P26678, P0DP23, P61586, Q13370, Q13009 | GNAS, PIK3CB, PLN, CALM1, RHOA, PDE3B, TIAM1 | More | |
Levonorgestrel | hsa04062 | Chemokine signaling pathway | 9.23E-03 | 10 | P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | |
Levonorgestrel | hsa04064 | NF-kappa B signaling pathway | 4.58E-03 | 4 | Q13489, Q13546, Q9UDY8, Q9UNE0 | BIRC3, RIPK1, MALT1, EDAR | More | |
Levonorgestrel | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | |
Levonorgestrel | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | |
Levonorgestrel | hsa04072 | Phospholipase D signaling pathway | 2.75E-02 | 3 | P61586, O14986, P63092 | RHOA, PIP5K1B, GNAS | More | |
Levonorgestrel | hsa04080 | Neuroactive ligand-receptor interaction | 3.70E-02 | 7 | P08311, P48058, Q15722, Q9H228, P43657, P21730, P35318 | CTSG, GRIA4, LTB4R, EDG8, P2RY5, C5AR1, ADM | More | |
Levonorgestrel | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
Levonorgestrel | hsa04114 | Oocyte meiosis | 3.19E-03 | 5 | P51812, Q02750, P16298, Q17RY0, P08069 | RPS6KA3, MAP2K1, PPP3CB, CPEB4, IGF1R | More | |
Levonorgestrel | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Levonorgestrel | hsa04122 | Sulfur relay system | 3.18E-02 | 1 | Q16762 | TST | More | |
Levonorgestrel | hsa04137 | Mitophagy - animal | 2.52E-02 | 2 | P19784, P67870 | CSNK2A2, CSNK2B | More | |
Levonorgestrel | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa04141 | Protein processing in endoplasmic reticulum | 2.78E-02 | 3 | P07384, O95487, O95816 | CAPN1, SEC24B, BAG2 | More | |
Levonorgestrel | hsa04150 | mTOR signaling pathway | 7.74E-03 | 4 | P08069, Q02750, Q9NQL2, P51812 | IGF1R, MAP2K1, RRAGD, RPS6KA3 | More | |
Levonorgestrel | hsa04151 | PI3K-Akt signaling pathway | 1.89E-03 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | |
Levonorgestrel | hsa04152 | AMPK signaling pathway | 2.07E-03 | 3 | P08069, Q96EB6, P36956 | IGF1R, SIRT1, SREBF1 | More | |
Levonorgestrel | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
Levonorgestrel | hsa04211 | Longevity regulating pathway | 1.34E-03 | 4 | Q12778, P08069, Q9UEF7, Q96KQ7 | FOXO1, IGF1R, KL, EHMT2 | More | |
Levonorgestrel | hsa04213 | Longevity regulating pathway - multiple species | 2.83E-03 | 3 | P08069, Q9Y4H2, Q13547 | IGF1R, IRS2, HDAC1 | More | |
Levonorgestrel | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
Levonorgestrel | hsa04217 | Necroptosis | 1.85E-03 | 7 | P01375, P01568, P48023, Q13489, Q13546, Q14765, Q99878 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT4, H2AC14 | More | |
Levonorgestrel | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
Levonorgestrel | hsa04310 | Wnt signaling pathway | 4.17E-03 | 3 | P61586, P19784, P67870 | RHOA, CSNK2A2, CSNK2B | More | |
Levonorgestrel | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
Levonorgestrel | hsa04360 | Axon guidance | 1.58E-04 | 8 | P16333, P20827, O95631, P42338, P07332, P23528, P19174, Q06124 | NCK1, EFNA1, NTN1, PIK3CB, FES, CFL1, PLCG1, PTPN11 | More | |
Levonorgestrel | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
Levonorgestrel | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | |
Levonorgestrel | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
Levonorgestrel | hsa04510 | Focal adhesion | 8.84E-03 | 4 | O14986, P61586, Q16363, P08069 | PIP5K1B, RHOA, LAMA4, IGF1R | More | |
Levonorgestrel | hsa04512 | ECM-receptor interaction | 3.73E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | |
Levonorgestrel | hsa04514 | Cell adhesion molecules | 8.19E-03 | 3 | P16109, P56750, O00501 | SELP, CLDN17, CLDN5 | More | |
Levonorgestrel | hsa04520 | Adherens junction | 1.65E-05 | 4 | P08069, P19784, P67870, P61586 | IGF1R, CSNK2A2, CSNK2B, RHOA | More | |
Levonorgestrel | hsa04530 | Tight junction | 1.64E-06 | 8 | Q8TEU7, P63261, P16989, P56750, O00501, Q9Y478, Q92974, Q14247 | RAPGEF6, ACTG1, CSDA, CLDN17, CLDN5, PRKAB1, ARHGEF2, CTTN | More | |
Levonorgestrel | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa04610 | Complement and coagulation cascades | 1.03E-03 | 3 | P25116, P09871, P0C0L4 | F2R, C1S, C4A | More | |
Levonorgestrel | hsa04611 | Platelet activation | 5.18E-05 | 5 | P25116, P08514, Q15746, Q8WYR1, P07359 | F2R, ITGA2B, MYLK, PIK3R5, GP1BA | More | |
Levonorgestrel | hsa04613 | Neutrophil extracellular trap formation | 1.07E-05 | 11 | P16109, P11215, Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431, P08514, P07359 | SELP, ITGAM, HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ITGA2B, GP1BA | More | |
Levonorgestrel | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | |
Levonorgestrel | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
Levonorgestrel | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
Levonorgestrel | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
Levonorgestrel | hsa04640 | Hematopoietic cell lineage | 1.37E-03 | 10 | P13612, P21926, P14778, P27930, P15144, P07766, P09693, P01732, P01730, P09564 | ITGA4, CD9, IL1R1, IL1R2, ANPEP, CD3E, CD3G, CD8A, CD4, CD7 | More | |
Levonorgestrel | hsa04650 | Natural killer cell mediated cytotoxicity | 9.90E-05 | 12 | P16298, P50591, P78314, P06239, O60880, P20963, Q02750, Q13241, P26718, O75015, P26717, P26715 | PPP3CB, TNFSF10, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | |
Levonorgestrel | hsa04657 | IL-17 signaling pathway | 3.31E-02 | 3 | P49841, P14780, P01375 | GSK3B, MMP9, TNF | More | |
Levonorgestrel | hsa04658 | Th1 and Th2 cell differentiation | 1.27E-04 | 9 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, P23771, Q9UL17 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, GATA3, TBX21 | More | |
Levonorgestrel | hsa04659 | Th17 cell differentiation | 3.35E-07 | 18 | P25963, Q04759, Q16539, P19174, P01730, P06239, P42224, P14784, P14778, P40189, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | NFKBIA, PRKCQ, MAPK14, PLCG1, CD4, LCK, STAT1, IL2RB, IL1R1, IL6ST, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | |
Levonorgestrel | hsa04660 | T cell receptor signaling pathway | 6.29E-04 | 10 | Q04759, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | PRKCQ, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | |
Levonorgestrel | hsa04662 | B cell receptor signaling pathway | 9.03E-05 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | |
Levonorgestrel | hsa04664 | Fc epsilon RI signaling pathway | 1.29E-03 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | |
Levonorgestrel | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | |
Levonorgestrel | hsa04713 | Circadian entrainment | 4.94E-02 | 2 | P62873, P63092 | GNB1, GNAS | More | |
Levonorgestrel | hsa04714 | Thermogenesis | 1.25E-02 | 3 | P15336, P63261, Q9Y478 | ATF2, ACTG1, PRKAB1 | More | |
Levonorgestrel | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
Levonorgestrel | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | |
Levonorgestrel | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Levonorgestrel | hsa04723 | Retrograde endocannabinoid signaling | 4.94E-02 | 2 | P48169, P62873 | GABRA4, GNB1 | More | |
Levonorgestrel | hsa04724 | Glutamatergic synapse | 2.85E-03 | 5 | P43003, P63092, P62873, P50151, P15104 | SLC1A3, GNAS, GNB1, GNG10, GLUL | More | |
Levonorgestrel | hsa04726 | Serotonergic synapse | 2.52E-02 | 2 | P63092, P62873 | GNAS, GNB1 | More | |
Levonorgestrel | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa04810 | Regulation of actin cytoskeleton | 2.58E-02 | 3 | Q15746, P08514, P25116 | MYLK, ITGA2B, F2R | More | |
Levonorgestrel | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
Levonorgestrel | hsa04913 | Ovarian steroidogenesis | 8.40E-04 | 2 | P06213, P08069 | INSR, IGF1R | More | |
Levonorgestrel | hsa04914 | Progesterone-mediated oocyte maturation | 9.67E-04 | 7 | P08069, Q17RY0, P42338, Q13370, P08238, P51812, Q02750 | IGF1R, CPEB4, PIK3CB, PDE3B, HSP90AB1, RPS6KA3, MAP2K1 | More | |
Levonorgestrel | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
Levonorgestrel | hsa04920 | Adipocytokine signaling pathway | 2.80E-02 | 2 | Q06124, Q9Y478 | PTPN11, PRKAB1 | More | |
Levonorgestrel | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | |
Levonorgestrel | hsa04924 | Renin secretion | 3.77E-02 | 2 | Q13370, P0DP23 | PDE3B, CALM1 | More | |
Levonorgestrel | hsa04930 | Type II diabetes mellitus | 3.14E-02 | 1 | P06213 | INSR | More | |
Levonorgestrel | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
Levonorgestrel | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
Levonorgestrel | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.11E-03 | 6 | P84022, Q13485, P10415, P42338, P49767, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PLCG1 | More | |
Levonorgestrel | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Levonorgestrel | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | |
Levonorgestrel | hsa04964 | Proximal tubule bicarbonate reclamation | 4.53E-03 | 2 | P00918, P49448 | CA2, GLUD2 | More | |
Levonorgestrel | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
Levonorgestrel | hsa04972 | Pancreatic secretion | 3.65E-02 | 2 | P63092, P61586 | GNAS, RHOA | More | |
Levonorgestrel | hsa04975 | Fat digestion and absorption | 9.50E-04 | 1 | O14494 | PLPP1 | More | |
Levonorgestrel | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | |
Levonorgestrel | hsa05032 | Morphine addiction | 2.47E-03 | 3 | P62873, P48169, P63092 | GNB1, GABRA4, GNAS | More | |
Levonorgestrel | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Levonorgestrel | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.76E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | |
Levonorgestrel | hsa05130 | Pathogenic Escherichia coli infection | 2.02E-04 | 8 | Q14247, P56750, O00501, Q92974, P63261, P25116, Q06124, O95487 | CTTN, CLDN17, CLDN5, ARHGEF2, ACTG1, F2R, PTPN11, SEC24B | More | |
Levonorgestrel | hsa05132 | Salmonella infection | 5.76E-04 | 7 | P25963, Q13546, Q13489, P10415, Q9BQS8, O60282, P68371 | NFKBIA, RIPK1, BIRC3, BCL2, FYCO1, KIF5C, TUBB2C | More | |
Levonorgestrel | hsa05133 | Pertussis | 1.86E-03 | 3 | P09871, P0C0L4, Q02556 | C1S, C4A, IRF8 | More | |
Levonorgestrel | hsa05135 | Yersinia infection | 1.52E-02 | 6 | P13612, P06239, Q16539, P49841, P01730, P01732 | ITGA4, LCK, MAPK14, GSK3B, CD4, CD8A | More | |
Levonorgestrel | hsa05140 | Leishmaniasis | 4.50E-03 | 5 | P14598, O60603, P25963, P29350, Q15080 | NCF1, TLR2, NFKBIA, PTPN6, NCF4 | More | |
Levonorgestrel | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
Levonorgestrel | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Levonorgestrel | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
Levonorgestrel | hsa05146 | Amoebiasis | 2.10E-02 | 6 | P09341, P14778, P27930, P05089, P12814, P08311 | CXCL1, IL1R1, IL1R2, ARG1, ACTN1, CTSG | More | |
Levonorgestrel | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Levonorgestrel | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | |
Levonorgestrel | hsa05163 | Human cytomegalovirus infection | 2.09E-02 | 4 | P62873, P61586, P63092, P61769 | GNB1, RHOA, GNAS, B2M | More | |
Levonorgestrel | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | |
Levonorgestrel | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | |
Levonorgestrel | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
Levonorgestrel | hsa05200 | Pathways in cancer | 1.31E-03 | 21 | Q13751, P42338, P08238, P42224, P19174, P43246, P84022, Q13485, Q13547, P14923, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P14784, P40189 | LAMB3, PIK3CB, HSP90AB1, STAT1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IL2RB, IL6ST | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | P29375 | JARID1A | Lysine-specific demethylase 5A | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.79 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P29375 | JARID1A | Lysine-specific demethylase 5A | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.711 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P29375 | JARID1A | Lysine-specific demethylase 5A | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.764 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P29375 | JARID1A | Lysine-specific demethylase 5A | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14923 | JUP | Junction plakoglobin | -0.735 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P29375 | JARID1A | Lysine-specific demethylase 5A | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.748 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | P29375 | JARID1A | Lysine-specific demethylase 5A | P0DP23 | CALM1 | Calmodulin-1 | 0.755 | P29375 | JARID1A | Lysine-specific demethylase 5A | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.768 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P29375 | JARID1A | Lysine-specific demethylase 5A | P40189 | IL6ST | Interleukin-6 receptor subunit beta | 0.83 |
|
Levonorgestrel | hsa05202 | Transcriptional misregulation in cancer | 8.55E-04 | 5 | P27930, P11215, P08069, Q13547, P12980 | IL1R2, ITGAM, IGF1R, HDAC1, LYL1 | More | |
Levonorgestrel | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
Levonorgestrel | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Levonorgestrel | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
Levonorgestrel | hsa05211 | Renal cell carcinoma | 1.06E-02 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | |
Levonorgestrel | hsa05212 | Pancreatic cancer | 2.34E-04 | 5 | P42338, P42224, P84022, Q13485, O75293 | PIK3CB, STAT1, SMAD3, SMAD4, GADD45B | More | |
Levonorgestrel | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | |
Levonorgestrel | hsa05214 | Glioma | 1.88E-03 | 4 | P08069, P0DP23, P42338, O75293 | IGF1R, CALM1, PIK3CB, GADD45B | More | |
Levonorgestrel | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
Levonorgestrel | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa05220 | Chronic myeloid leukemia | 1.44E-03 | 6 | Q13547, Q13485, P25963, P84022, P42338, O75293 | HDAC1, SMAD4, NFKBIA, SMAD3, PIK3CB, GADD45B | More | |
Levonorgestrel | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
Levonorgestrel | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
Levonorgestrel | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | |
Levonorgestrel | hsa05226 | Gastric cancer | 4.33E-03 | 5 | Q02750, O15169, P84022, Q13485, P10415 | MAP2K1, AXIN1, SMAD3, SMAD4, BCL2 | More | |
Levonorgestrel | hsa05230 | Central carbon metabolism in cancer | 1.12E-02 | 1 | P11413 | G6PD | More | |
Levonorgestrel | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.92E-04 | 8 | P07766, P20963, P09693, P06239, Q04759, Q16539, Q9HC35, P01730 | CD3E, CD247, CD3G, LCK, PRKCQ, MAPK14, EML4, CD4 | More | |
Levonorgestrel | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Levonorgestrel | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Levonorgestrel | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Levonorgestrel | hsa05340 | Primary immunodeficiency | 2.90E-04 | 5 | P01730, P01732, P11912, P07766, P06239 | CD4, CD8A, CD79A, CD3E, LCK | More | |
Levonorgestrel | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
Levonorgestrel | hsa05415 | Diabetic cardiomyopathy | 3.59E-02 | 1 | P11413 | G6PD | More | |
Levonorgestrel | hsa05418 | Fluid shear stress and atherosclerosis | 3.73E-02 | 4 | P42338, P14598, P0DP23, P08238 | PIK3CB, NCF1, CALM1, HSP90AB1 | More | |